Literature DB >> 16377680

In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections.

Ellie J C Goldstein1, Diane M Citron, Yumi A Warren, Kerin L Tyrrell, C Vreni Merriam, Helen Fernandez.   

Abstract

The in vitro activity of moxifloxacin against 923 recent anaerobic isolates obtained from pretreatment cultures in patients with complicated intra-abdominal infections was studied using the CLSI M11-A-6 agar dilution method. Moxifloxacin was active against 87% (96 of 110) Bacteroides fragilis strains at < or = 1 microg/ml and 87% (79 of 90) B. thetaiotaomicron strains at < or = 2 microg/ml. Species variation was seen, with B. uniformis, B. vulgatus, Clostridium clostridioforme, and C. symbiosum being least susceptible and accounting for most of the resistant isolates; excluding the aforementioned four resistant species, 86% (303 of 363) of Bacteroides species isolates and 94% (417 of 450) of all other genera and species were susceptible to < or = 2 microg/ml of moxifloxacin. Overall, moxifloxacin was active against 763 of 923 (83%) of strains at < or = 2 microg/ml, supporting its use as a monotherapy for some community-acquired intra-abdominal infections.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16377680      PMCID: PMC1346786          DOI: 10.1128/AAC.50.1.148-155.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria.

Authors:  G Ackermann; R Schaumann; B Pless; M C Claros; E J Goldstein; A C Rodloff
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-03       Impact factor: 3.267

2.  Comparative in vitro activities of gemifloxacin, other quinolones, and nonquinolone antimicrobials against obligately anaerobic bacteria.

Authors:  N Kleinkauf; G Ackermann; R Schaumann; A C Rodloff
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections.

Authors:  Joseph S Solomkin; John E Mazuski; Ellen J Baron; Robert G Sawyer; Avery B Nathens; Joseph T DiPiro; Timothy Buchman; E Patchen Dellinger; John Jernigan; Sherwood Gorbach; Anthony W Chow; John Bartlett
Journal:  Clin Infect Dis       Date:  2003-09-25       Impact factor: 9.079

4.  Susceptibility of the Bacteroides fragilis group to newer quinolones and other standard anti-anaerobic agents.

Authors:  R Horn; H G Robson
Journal:  J Antimicrob Chemother       Date:  2001-07       Impact factor: 5.790

5.  In vitro activities of newer quinolones against bacteroides group organisms.

Authors:  D R Snydman; N V Jacobus; L A McDermott; R Ruthazer; E Goldstein; S Finegold; L Harrell; D W Hecht; S Jenkins; C Pierson; R Venezia; J Rihs; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

6.  Emergence of fluoroquinolone resistance among Bacteroides species.

Authors:  Yoav Golan; Laura A McDermott; Nilda V Jacobus; Ellie J C Goldstein; Sydney Finegold; Lizzie J Harrell; David W Hecht; Stephen G Jenkins; C Pierson; Richard Venezia; Jack Rihs; Paul Iannini; Sherwood L Gorbach; David R Snydman
Journal:  J Antimicrob Chemother       Date:  2003-07-15       Impact factor: 5.790

7.  Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli.

Authors:  Reiner Schaumann; Rosemarie Blatz; Joerg Beer; Grit Ackermann; Arne C Rodloff
Journal:  J Antimicrob Chemother       Date:  2004-01-16       Impact factor: 5.790

8.  Bacteremia due to Bacteroides fragilis group: distribution of species, beta-lactamase production, and antimicrobial susceptibility patterns.

Authors:  Kenneth E Aldridge; Deborah Ashcraft; Megan O'Brien; Charles V Sanders
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

9.  Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria.

Authors:  C Edlund; S Sabouri; C E Nord
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-03       Impact factor: 3.267

10.  In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections.

Authors:  Charles E Edmiston; Candace J Krepel; Gary R Seabrook; Lewis R Somberg; Atilla Nakeeb; Robert A Cambria; Jonathan B Towne
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

View more
  18 in total

1.  Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents.

Authors:  Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi A Warren; Kerin L Tyrrell; Helen T Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

Review 2.  Antianaerobic antimicrobials: spectrum and susceptibility testing.

Authors:  Itzhak Brook; Hannah M Wexler; Ellie J C Goldstein
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

3.  In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections.

Authors:  Ellie J C Goldstein; Diane M Citron; Yumi A Warren; Kerin L Tyrrell; C Vreni Merriam; Helen T Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

4.  Canadian practice guidelines for surgical intra-abdominal infections.

Authors:  Anthony W Chow; Gerald A Evans; Avery B Nathens; Chad G Ball; Glen Hansen; Godfrey Km Harding; Andrew W Kirkpatrick; Karl Weiss; George G Zhanel
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

Review 5.  Anaerobic infections: update on treatment considerations.

Authors:  Elisabeth Nagy
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

6.  A focus on intra-abdominal infections.

Authors:  Massimo Sartelli
Journal:  World J Emerg Surg       Date:  2010-03-19       Impact factor: 5.469

7.  National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.

Authors:  D R Snydman; N V Jacobus; L A McDermott; R Ruthazer; Y Golan; E J C Goldstein; S M Finegold; L J Harrell; D W Hecht; S G Jenkins; C Pierson; R Venezia; V Yu; J Rihs; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  2007-02-05       Impact factor: 5.191

Review 8.  Improving outcomes of elderly patients with community-acquired pneumonia.

Authors:  Félix Gutiérrez; Mar Masiá
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

9.  In vitro activities of moxifloxacin and tigecycline against bacterial isolates associated with intraabdominal infections at a medical center in Taiwan, 2001-2006.

Authors:  C-Y Liu; C-L Lu; Y-T Huang; C-H Liao; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-09-08       Impact factor: 3.267

10.  Antimicrobial susceptibilities and clinical sources of Dialister species.

Authors:  F Morio; H Jean-Pierre; L Dubreuil; E Jumas-Bilak; L Calvet; G Mercier; R Devine; H Marchandin
Journal:  Antimicrob Agents Chemother       Date:  2007-10-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.